CymaBay Therapeutics Inc. (CBAY) financial statements (2021 and earlier)

Company profile

Business Address 7575 GATEWAY BOULEVARD
NEWARK, CA 94560
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:146161169176 219
Cash and cash equivalents28479657 43
Short-term investments11811473119 175
Other undisclosed cash, cash equivalents, and short-term investments(0)0(0)(0) 0
Prepaid expense3111 1
Other undisclosed current assets3448 8
Total current assets:152166174186 228
Noncurrent Assets
Operating lease, right-of-use asset0000 0
Property, plant and equipment2222 3
Other noncurrent assets0000 1
Total noncurrent assets:2223 4
TOTAL ASSETS:154168177189 232
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9533 7
Accounts payable0101 1
Accrued liabilities5432 5
Employee-related liabilities4     
Restructuring reserve0012  
Other undisclosed current liabilities1657 11
Total current liabilities:1010912 17
Noncurrent Liabilities
Long-term debt and lease obligation1122 2
Operating lease, liability1122 2
Other undisclosed noncurrent liabilities(1)(1)(2)   
Total noncurrent liabilities: 122 2
Total liabilities:11121114 19
Stockholders' equity
Stockholders' equity attributable to parent143157166175 213
Common stock0000 0
Additional paid in capital820818815814 809
Accumulated other comprehensive income (loss)000(0) 0
Accumulated deficit(677)(661)(650)(639) (596)
Total stockholders' equity:143157166175 213
TOTAL LIABILITIES AND EQUITY:154168177189 232

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
Operating expenses(16)(12)(11)(14) (28)
Operating loss:(16)(12)(11)(14) (28)
Nonoperating income
(Investment Income, Nonoperating)
0001 1
Net loss available to common stockholders, diluted:(16)(11)(11)(13) (26)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
Net loss:(16)(11)(11)(13) (26)
Other comprehensive income (loss)(0)(0)0(0) (0)
Comprehensive loss, net of tax, attributable to parent:(16)(12)(10)(13) (26)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: